File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease (IBD) Working Party guidelines on IBD management during the COVID‐19 pandemic

TitleAsian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease (IBD) Working Party guidelines on IBD management during the COVID‐19 pandemic
Authors
KeywordsCOVID‐19
Crohn's disease
inflammatory bowel diseases
ulcerative colitis
Issue Date2020
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at https://onlinelibrary.wiley.com/loi/23979070
Citation
JGH Open, 2020, v. 4 n. 3, p. 320-323 How to Cite?
AbstractThe COVID-19 pandemic, secondary to SARS-CoV-2, has resulted in high mortality and morbidity worldwide. As inflammatory bowel disease (IBD) is a chronic disease, and most patients are on long-term immunosuppressive agents, there is understandable concern, particularly in terms of therapy. In view of this, experts in IBD across the Asia Pacific region were invited to put together recommendations based on their experience and the currently available data. In general, most IBD therapies (with a few exceptions) can be continued safely, and the general consensus is that maintaining disease control should remain the main principle of management. In addition, social distancing measures and the appropriate use of personal protective equipment should be strictly adhered to. During the current pandemic, face-to-face clinic follow ups and non-urgent procedures should be kept to a minimum.
Persistent Identifierhttp://hdl.handle.net/10722/284582
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorLing, KL-
dc.contributor.authorHilmi, I-
dc.contributor.authorRaja Ali, RA-
dc.contributor.authorLeong, RWL-
dc.contributor.authorLeung, WK-
dc.contributor.authorNg, SC-
dc.contributor.authorWu, KC-
dc.contributor.authorChen, MH-
dc.contributor.authorRan, ZH-
dc.contributor.authorHisamatsu, T-
dc.contributor.authorAhuja, V-
dc.contributor.authorMakharia, GK-
dc.contributor.authorBanerjee, R-
dc.contributor.authorWei, SC-
dc.contributor.authorWu, DC-
dc.contributor.authorPisespongsa, P-
dc.contributor.authorYe, BD-
dc.contributor.authorSollano, J-
dc.contributor.authorSimadibrata, M-
dc.contributor.authorChuah, SW-
dc.contributor.authorOoi, CJ-
dc.date.accessioned2020-08-07T08:59:41Z-
dc.date.available2020-08-07T08:59:41Z-
dc.date.issued2020-
dc.identifier.citationJGH Open, 2020, v. 4 n. 3, p. 320-323-
dc.identifier.urihttp://hdl.handle.net/10722/284582-
dc.description.abstractThe COVID-19 pandemic, secondary to SARS-CoV-2, has resulted in high mortality and morbidity worldwide. As inflammatory bowel disease (IBD) is a chronic disease, and most patients are on long-term immunosuppressive agents, there is understandable concern, particularly in terms of therapy. In view of this, experts in IBD across the Asia Pacific region were invited to put together recommendations based on their experience and the currently available data. In general, most IBD therapies (with a few exceptions) can be continued safely, and the general consensus is that maintaining disease control should remain the main principle of management. In addition, social distancing measures and the appropriate use of personal protective equipment should be strictly adhered to. During the current pandemic, face-to-face clinic follow ups and non-urgent procedures should be kept to a minimum.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at https://onlinelibrary.wiley.com/loi/23979070-
dc.relation.ispartofJGH Open-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCOVID‐19-
dc.subjectCrohn's disease-
dc.subjectinflammatory bowel diseases-
dc.subjectulcerative colitis-
dc.titleAsian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease (IBD) Working Party guidelines on IBD management during the COVID‐19 pandemic-
dc.typeArticle-
dc.identifier.emailLeung, WK: waikleung@hku.hk-
dc.identifier.authorityLeung, WK=rp01479-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1002/jgh3.12362-
dc.identifier.pmid32514431-
dc.identifier.pmcidPMC7273734-
dc.identifier.scopuseid_2-s2.0-85085969508-
dc.identifier.hkuros312505-
dc.identifier.volume4-
dc.identifier.issue3-
dc.identifier.spage320-
dc.identifier.epage323-
dc.identifier.eissn2397-9070-
dc.publisher.placeAustralia-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats